Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

References for PMC Articles for PubMed (Select 22438770)

1.

Tumor-recruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation.

Bekes EM, Schweighofer B, Kupriyanova TA, Zajac E, Ardi VC, Quigley JP, Deryugina EI.

Am J Pathol. 2011 Sep;179(3):1455-70. doi: 10.1016/j.ajpath.2011.05.031. Epub 2011 Jul 8.

2.

Insulin-like growth factor pathway: a link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer?

Aggarwal RR, Ryan CJ, Chan JM.

Urol Oncol. 2013 Jul;31(5):522-30. doi: 10.1016/j.urolonc.2011.05.001. Epub 2011 Jun 12. Review.

PMID:
21658978
3.

Loss of EGFR induced autophagy sensitizes hormone refractory prostate cancer cells to adriamycin.

Xu S, Weihua Z.

Prostate. 2011 Aug 1;71(11):1216-24. doi: 10.1002/pros.21337. Epub 2011 Jan 12.

PMID:
21656832
4.

Prenylated c17orf37 induces filopodia formation to promote cell migration and metastasis.

Dasgupta S, Cushman I, Kpetemey M, Casey PJ, Vishwanatha JK.

J Biol Chem. 2011 Jul 22;286(29):25935-46. doi: 10.1074/jbc.M111.254599. Epub 2011 May 31.

5.

Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer.

Mukherjee R, McGuinness DH, McCall P, Underwood MA, Seywright M, Orange C, Edwards J.

Br J Cancer. 2011 Jun 7;104(12):1920-8. doi: 10.1038/bjc.2011.163. Epub 2011 May 10.

6.

Relationship of insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) gene polymorphism with the susceptibility to development of prostate cancer and influence on serum levels of IGF-I, and IGFBP-3.

Safarinejad MR, Shafiei N, Safarinejad S.

Growth Horm IGF Res. 2011 Jun;21(3):146-54. doi: 10.1016/j.ghir.2011.03.008. Epub 2011 May 4.

PMID:
21536469
7.

Wnt signaling in prostate development and carcinogenesis.

Kharaishvili G, Simkova D, Makharoblidze E, Trtkova K, Kolar Z, Bouchal J.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2011 Mar;155(1):11-8. Review.

8.

Insulin-like growth factor 1 stimulation of androgen receptor activity requires β(1A) integrins.

Sayeed A, Alam N, Trerotola M, Languino LR.

J Cell Physiol. 2012 Feb;227(2):751-8. doi: 10.1002/jcp.22784.

9.
10.

Regulation of VEGF, MMP-9 and metastasis by CXCR4 in a prostate cancer cell line.

Wang Q, Diao X, Sun J, Chen Z.

Cell Biol Int. 2011 Sep;35(9):897-904. doi: 10.1042/CBI20100744.

PMID:
21306303
11.

Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer.

Peraldo-Neia C, Migliardi G, Mello-Grand M, Montemurro F, Segir R, Pignochino Y, Cavalloni G, Torchio B, Mosso L, Chiorino G, Aglietta M.

BMC Cancer. 2011 Jan 25;11:31. doi: 10.1186/1471-2407-11-31.

12.

Estrogens promote invasion of prostate cancer cells in a paracrine manner through up-regulation of matrix metalloproteinase 2 in prostatic stromal cells.

Yu L, Wang CY, Shi J, Miao L, Du X, Mayer D, Zhang J.

Endocrinology. 2011 Mar;152(3):773-81. doi: 10.1210/en.2010-1239. Epub 2011 Jan 19.

PMID:
21248144
13.

mTOR: from growth signal integration to cancer, diabetes and ageing.

Zoncu R, Efeyan A, Sabatini DM.

Nat Rev Mol Cell Biol. 2011 Jan;12(1):21-35. doi: 10.1038/nrm3025. Epub 2010 Dec 15. Review.

14.

Wnt/β-catenin activation promotes prostate tumor progression in a mouse model.

Yu X, Wang Y, DeGraff DJ, Wills ML, Matusik RJ.

Oncogene. 2011 Apr 21;30(16):1868-79. doi: 10.1038/onc.2010.560. Epub 2010 Dec 13.

15.

Serial analysis of resected prostate cancer suggests up-regulation of type 1 IGF receptor with disease progression.

Turney BW, Turner GD, Brewster SF, Macaulay VM.

BJU Int. 2011 May;107(9):1488-99. doi: 10.1111/j.1464-410X.2010.09556.x. Epub 2010 Sep 14.

PMID:
20840329
16.

Matrix metalloproteinase 9 is associated with Gleason score in prostate cancer but not with prognosis.

Trudel D, Fradet Y, Meyer F, Têtu B.

Hum Pathol. 2010 Dec;41(12):1694-701. doi: 10.1016/j.humpath.2010.05.001. Epub 2010 Sep 9.

PMID:
20825973
17.

Her-2/neu expression in prostate adenocarcinoma: a systematic review and meta-analysis.

Neto AS, Tobias-Machado M, Wroclawski ML, Fonseca FL, Teixeira GK, Amarante RD, Wroclawski ER, Del Giglio A.

J Urol. 2010 Sep;184(3):842-50. doi: 10.1016/j.juro.2010.04.077. Review.

PMID:
20663525
18.

HER-2/neu as a target for cancer vaccines.

Baxevanis CN, Voutsas IF, Gritzapis AD, Perez SA, Papamichail M.

Immunotherapy. 2010 Mar;2(2):213-26. doi: 10.2217/imt.09.89. Review.

PMID:
20635929
19.

NKX3.1 as a marker of prostatic origin in metastatic tumors.

Gurel B, Ali TZ, Montgomery EA, Begum S, Hicks J, Goggins M, Eberhart CG, Clark DP, Bieberich CJ, Epstein JI, De Marzo AM.

Am J Surg Pathol. 2010 Aug;34(8):1097-105. doi: 10.1097/PAS.0b013e3181e6cbf3.

20.

Integrative genomic profiling of human prostate cancer.

Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL.

Cancer Cell. 2010 Jul 13;18(1):11-22. doi: 10.1016/j.ccr.2010.05.026. Epub 2010 Jun 24.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk